Dye Imaging to Spot Leftover Tumor During Sarcoma Surgery
Tests an injected green dye and imaging device to find leftover sarcoma during surgery.
Plain-language title generated from the registry record
Registry title: Fluorescent Intra-operative Tumor Margin Examination
Key facts
- Where
- Pittsburgh, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT04719156, who can take part
Where in United States
- UPMC-Shadyside HospitalPittsburgh, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kurt Weiss
- Trial code
- NCT04719156
- Record updated
- 20 February 2026
- Original description
Tumor margin confirmation is important to confirming appropriate disease excision. Current standard of care is to take select margin samples to pathology for intra-operative readings. However, this is expensive, time consuming, and only assesses the margin contained within the specific sample. In prior work the investigators have determined that indocyanine green (ICG) is highly specific to the tumor bed when injected shortly before surgery. The investigators hypothesize that ICG will be able to accurately identify residual positive tumor margins during sarcoma excision procedures.Read full original descriptionShow less
Evaluation of Intraoperative Tumor Margin Identification With Fluorescent Dye Imaging
Tumor margin confirmation is important to confirming appropriate disease excision. Current standard of care is to take select margin samples to pathology for intra-operative readings. However, this is expensive, time consuming, and only assesses the margin contained within the specific sample. In prior work the investigators have determined that indocyanine green (ICG) is highly specific to the tumor bed when injected shortly before surgery. The investigators hypothesize that ICG will be able to accurately identify residual positive tumor margins during sarcoma excision procedures.
Inclusion: Patients above the age of 18 with a primary musculoskeletal tumor that has been indicated for surgical excision by a fellowship trained orthopaedic oncologist; Surgical consent was obtained prior to research consent; Patients with a biopsy-confirmed primary soft tissue or bone tumor that has not been previously excised and has a known risk of local or remote recurrence.
Exclusion: Prior surgery local to the mass being excised; Patients with a history of anaphylactic reaction to contrast media or fluorescein allergy; Dialysis, renal failure, uremia; Patients below the age of 18; Pregnancy, breast feeding; Non- or minimally-recurrent masses (i.e. osteochondroma).